

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



Atty. Docket No.: PU3552US2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Harris et al

Serial No.: 10/669,400

Examiner: S. Patel

Filing Date: September 23, 2003

Art Unit: 1624

Allowed: April 9, 2004

Confirmation No.: 3962

For: SUBSTITUTED AZA-OXINDOLE DERIVATIVES

Box Issue Fee  
Commissioner for Patents  
Washington D.C. 20231

**AMENDMENT UNDER 37 C.F.R. 1.312**

Sir:


This paper is filed, after receipt of Notice of Allowance and with payment of the Issue Fee, under 37 C.F.R. 1.312 to make of record an Information Disclosure Statement (IDS) and Forms 1449, which are of record in parent case 09/914,393 (U.S. Patent 6,624,171). Upon review of the subject application in preparation for payment of the Issue Fee, Applicants have noted that an IDS and forms 1449 that formally makes of record references cited in the parent application appears to not have been submitted to the Patent Office. It appears that the Examiner has considered such references (see paragraph 3 of the Reasons for Allowance). Applicants now wish to submit such IDS and forms 1449 to complete the record and request that Examiner return signed off copies of the same to Applicants.

Should any issues remain unresolved in this application which would bar issuance, the Examiner is invited to contact the undersigned Attorney at (919) 483-8247, to discuss such issues. Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to

Atty. Docket No.: PU3552US2

effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

  
John L. Lemanowicz  
Attorney for Applicants  
Registration No. 37,380

Date: 30 June, 2004  
Glaxo Wellcome Inc.  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709  
(919) 483-8247